Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3,4-diaminopyridine for Fatigue in Multiple Sclerosis
NCT00190268Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2005
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing 3,4-diaminopyridine with Placebo (2 arms). Primary endpoint: Echelle de Mesure de l'Impact de la Fatigue dans la SEP at 43 months. Started Feb 2005; status: completed.
02
Drugs
amifampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00190268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190268.